These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 866829)
21. [Clinical significance of cramps of the lower extremities in patients with parkinsonism]. Yu HZ Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911 [No Abstract] [Full Text] [Related]
25. Newly-diagnosed Parkinson's disease: a therapeutic update. Pleet AB Geriatrics; 1992 Jan; 47(1):24-9. PubMed ID: 1729144 [TBL] [Abstract][Full Text] [Related]
26. [Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2005 Jul; 28(7):245-6. PubMed ID: 16038123 [No Abstract] [Full Text] [Related]
27. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. Klivényi P; Vécsei L Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774 [TBL] [Abstract][Full Text] [Related]
29. [Present-day treatment of parkinsonism in the aged]. Siegfried J Schweiz Rundsch Med Prax; 1973 Oct; 62(40):1202-3. PubMed ID: 4754539 [No Abstract] [Full Text] [Related]
30. Inhibitors of dopamine inactivating systems as antiparkinson drugs. Youdim MB Adv Neurol; 1990; 53():483-8. PubMed ID: 2239488 [No Abstract] [Full Text] [Related]
31. What to do when Sinemet fails: Part one. Klawans HL Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692 [No Abstract] [Full Text] [Related]
32. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine]. Mizuno Y; Yoshida M; Obayashi T; Ueki A Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921 [No Abstract] [Full Text] [Related]
33. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease]. Dessibourg CA; Gachoud JP Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341 [TBL] [Abstract][Full Text] [Related]
34. Renaissance of amantadine in the treatment of Parkinson's disease. Blanchet PJ; Metman LV; Chase TN Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683 [No Abstract] [Full Text] [Related]
35. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies]. Namba S; Omoto T; Kishikawa H No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033 [No Abstract] [Full Text] [Related]
36. [L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism]. Arai H; Shinotoh H; Hattori T Rinsho Shinkeigaku; 1997 Mar; 37(3):264-5. PubMed ID: 9217430 [TBL] [Abstract][Full Text] [Related]
37. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Facca A; Sanchez-Ramos J Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153 [No Abstract] [Full Text] [Related]
38. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine". Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824 [TBL] [Abstract][Full Text] [Related]
39. Combined treatment in Parkinson's disease. Wheatley D Practitioner; 1983 Mar; 227(1377):446-7. PubMed ID: 6889232 [No Abstract] [Full Text] [Related]
40. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor]. Meco G; Casacchia M; Zamponi A; Agnoli A Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]